For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative expenses | 9,354,135 | |||
| Research and development expenses | 4,100,168 | |||
| Depreciation expense | 6,874 | |||
| Total operating expenses | 13,461,177 | |||
| Loss from operations | -13,461,177 | |||
| Interest and dividend income | 223,815 | |||
| Total other income | 223,815 | |||
| Net loss and comprehensive loss | -13,237,362 | |||
| Basic EPS | -6.64 | |||
| Diluted EPS | -6.64 | |||
| Basic Average Shares | 1,993,757 | |||
| Diluted Average Shares | 1,993,757 | |||
Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. (CVKD)